Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Biomedical Innovation topic
No spam. Unsubscribe anytime.
Chair urges streamlining FDA reviews to keep U.S. lead in biomedical innovation
Summary
The Chair opened a subcommittee hearing calling on Congress to use next year's FDA user-fee reauthorization to reduce administrative burdens, expand modern trial designs and embed clinical trial networks in care—citing Operation Trialblazer as an HHS-wide effort to accelerate product development.
The Chair opened a subcommittee hearing urging Congress to reexamine regulatory processes so the United States remains the global leader in biopharmaceutical research. The Chair framed the upcoming FDA user-fee reauthorization as an opportunity to modernize drug development and speed patient access to new therapies.
The Chair noted that "other countries are catching up" and said Congress must "reexamine our current landscape to ensure we are staying up to date with the latest biopharmaceutical advancements." The Chair highlighted Operation Trialblazer, saying it was "announced in June" and that it is an HHS-wide effort to promote cross-agency collaboration and earlier support for research.
Explaining the rationale for user fees, the Chair said that for more than three decades the programs have provided FDA with resources to review drugs and devices without relying solely on taxpayer dollars. "User fees are paid by manufacturers that submit products for review, helping ensure the FDA has the scientific expertise and capacities necessary to keep pace with the rapidly advancing medical innovations," the Chair said.
The Chair described Operation Trialblazer as designed to "modernize and accelerate medical product development, aiming to remove the unnecessary hurdles and ambiguity that sometimes hinders patient access to innovative treatments," and urged encouraging modern trial designs and appropriate use of real-world evidence to shorten development timelines without compromising safety.
On trial access, the Chair urged embedding clinical trial networks in routine care and expanding access in rural areas so more patients can participate in research. The Chair also tied regulatory predictability to domestic investment, saying timely, predictable review can encourage companies to "invest, develop, and manufacture domestically."
"Thank the witnesses for being here this morning, and I look forward to the discussion," the Chair said, before moving to witness testimony. The hearing will feed into the subcommittee's work ahead of the FDA user-fee reauthorization next year.
